Literature DB >> 18829467

C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors.

Xinle Wu1, Bryan Lemon, XiaoFan Li, Jamila Gupte, Jennifer Weiszmann, Jennitte Stevens, Nessa Hawkins, Wenyan Shen, Richard Lindberg, Jin-Long Chen, Hui Tian, Yang Li.   

Abstract

FGF19 subfamily proteins (FGF19, FGF21, and FGF23) are unique members of fibroblast growth factors (FGFs) that regulate energy, bile acid, glucose, lipid, phosphate, and vitamin D homeostasis in an endocrine fashion. Their activities require the presence of alpha or betaKlotho, two related single-pass transmembrane proteins, as co-receptors in relevant target tissues. We previously showed that FGF19 can bind to both alpha and betaKlotho, whereas FGF21 and FGF23 can bind only to either betaKlotho or alphaKlotho, respectively in vitro. To determine the mechanism regulating the binding and specificity among FGF19 subfamily members to Klotho family proteins, chimeric proteins between FGF19 subfamily members or chimeric proteins between Klotho family members were constructed to probe the interaction between those two families. Our results showed that a chimera of FGF19 with the FGF21 C-terminal tail interacts only with betaKlotho and a chimera with the FGF23 C-terminal tail interacts only with alphaKlotho. FGF signaling assays also reflected the change of specificity we observed for the chimeras. These results identified the C-terminal tail of FGF19 as a region necessary for its recognition of Klotho family proteins. In addition, chimeras between alpha and betaKlotho were also generated to probe the regions in Klotho proteins that are important for signaling by this FGF subfamily. Both FGF23 and FGF21 require intact alpha or betaKlotho for signaling, respectively, whereas FGF19 can signal through a Klotho chimera consisting of the N terminus of alphaKlotho and the C terminus of betaKlotho. Our results provide the first glimpse of the regions that regulate the binding specificity between this unique family of FGFs and their co-receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829467      PMCID: PMC2662259          DOI: 10.1074/jbc.M803319200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system.

Authors:  Hiroshi Tsujikawa; Yoko Kurotaki; Toshihiko Fujimori; Kazuhiko Fukuda; Yo-Ichi Nabeshima
Journal:  Mol Endocrinol       Date:  2003-10-03

2.  The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity.

Authors:  Nicholas J Harmer; Luca Pellegrini; Dima Chirgadze; Juan Fernandez-Recio; Tom L Blundell
Journal:  Biochemistry       Date:  2004-01-27       Impact factor: 3.162

Review 3.  Structural basis for fibroblast growth factor receptor activation.

Authors:  Moosa Mohammadi; Shaun K Olsen; Omar A Ibrahimi
Journal:  Cytokine Growth Factor Rev       Date:  2005-04       Impact factor: 7.638

4.  Co-receptor requirements for fibroblast growth factor-19 signaling.

Authors:  Xinle Wu; Hongfei Ge; Jamila Gupte; Jennifer Weiszmann; Grant Shimamoto; Jennitte Stevens; Nessa Hawkins; Bryan Lemon; Wenyan Shen; Jing Xu; Murielle M Veniant; Yue-Sheng Li; Richard Lindberg; Jin-Long Chen; Hui Tian; Yang Li
Journal:  J Biol Chem       Date:  2007-08-21       Impact factor: 5.157

5.  Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production.

Authors:  Hitoshi Saito; Kenichiro Kusano; Masahiko Kinosaki; Hirotaka Ito; Michinori Hirata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2002-11-04       Impact factor: 5.157

6.  FGF-21 as a novel metabolic regulator.

Authors:  Alexei Kharitonenkov; Tatiyana L Shiyanova; Anja Koester; Amy M Ford; Radmila Micanovic; Elizabeth J Galbreath; George E Sandusky; Lisa J Hammond; Julie S Moyers; Rebecca A Owens; Jesper Gromada; Joseph T Brozinick; Eric D Hawkins; Victor J Wroblewski; De-Shan Li; Farrokh Mehrbod; S Richard Jaskunas; Armen B Shanafelt
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

7.  Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein.

Authors:  S Ito; S Kinoshita; N Shiraishi; S Nakagawa; S Sekine; T Fujimori; Y I Nabeshima
Journal:  Mech Dev       Date:  2000-11       Impact factor: 1.882

8.  Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity.

Authors:  Elizabeth Tomlinson; Ling Fu; Linu John; Bruce Hultgren; Xiaojian Huang; Mark Renz; Jean Philippe Stephan; Saio Ping Tsai; Lyn Powell-Braxton; Dorothy French; Timothy A Stewart
Journal:  Endocrinology       Date:  2002-05       Impact factor: 4.736

9.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Makoto Kakitani; Yuji Yamazaki; Hisashi Hasegawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Kazuma Tomizuka; Takeyoshi Yamashita
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

10.  Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

Authors:  Ling Fu; Linu M John; Sean H Adams; Xing Xian Yu; Elizabeth Tomlinson; Mark Renz; P Mickey Williams; Robert Soriano; Racquel Corpuz; Barbara Moffat; Richard Vandlen; Laura Simmons; Jessica Foster; Jean-Philippe Stephan; Siao Ping Tsai; Timothy A Stewart
Journal:  Endocrinology       Date:  2004-02-19       Impact factor: 4.736

View more
  35 in total

1.  Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor.

Authors:  Regina Goetz; Mutsuko Ohnishi; Serkan Kir; Hiroshi Kurosu; Lei Wang; Johanne Pastor; Jinghong Ma; Weiming Gai; Makoto Kuro-o; Mohammed S Razzaque; Moosa Mohammadi
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 2.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

3.  FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.

Authors:  Xinle Wu; Hongfei Ge; Bryan Lemon; Steven Vonderfecht; Jennifer Weiszmann; Randy Hecht; Jamila Gupte; Todd Hager; Zhulun Wang; Richard Lindberg; Yang Li
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

4.  Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.

Authors:  Xinle Wu; Hongfei Ge; Bryan Lemon; Jennifer Weiszmann; Jamila Gupte; Nessa Hawkins; Xiaofan Li; Jie Tang; Richard Lindberg; Yang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

5.  Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity.

Authors:  Ekaterina S Kuzina; Peter Man-Un Ung; Jyotidarsini Mohanty; Francisco Tome; Jungyuen Choi; Els Pardon; Jan Steyaert; Irit Lax; Avner Schlessinger; Joseph Schlessinger; Sangwon Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-03       Impact factor: 11.205

6.  Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.

Authors:  Masao Nakamura; Yuriko Uehara; Masahiro Asada; Emi Honda; Naoko Nagai; Koji Kimata; Masashi Suzuki; Toru Imamura
Journal:  J Biol Chem       Date:  2011-06-08       Impact factor: 5.157

7.  Biochemical and functional characterization of the klotho-VS polymorphism implicated in aging and disease risk.

Authors:  Tracey B Tucker Zhou; Gwendalyn D King; CiDi Chen; Carmela R Abraham
Journal:  J Biol Chem       Date:  2013-11-11       Impact factor: 5.157

Review 8.  Fibroblast growth factor 23 and acute kidney injury.

Authors:  Javier A Neyra; Orson W Moe; Ming Chang Hu
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

9.  Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis.

Authors:  Xinle Wu; Yang Li
Journal:  Aging (Albany NY)       Date:  2009-12-09       Impact factor: 5.682

10.  Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression.

Authors:  Shu Feng; Olga Dakhova; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2013-02-25       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.